Purpose:Cancer-related fatigue is a prevalent, debilitating condition that can persist for months or years after treatment. In a single-arm clinical trial, the feasibility and safety of a time-restricted eating (TRE) intervention were evaluated among cancer survivors, and initial estimates of within-person change in cancer-related fatigue were obtained. Methods:Participants were 4-60 months post-cancer treatment, were experiencing fatigue (≥ 3 on a scale 0-10), and were not following TRE. TRE entailed limiting all food and beverages to a self-selected 10-h window for 14 days. Participants reported their eating window in a daily diary and completed the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Brief Fatigue Inventory (BFI), and symptom inventory pre- and post-intervention. This study was pre-registered at clinicaltrials.gov in January 2020 (NCT04243512). Results:Participants (n=39) were 61.5 ± 12.4 years old and 1.8 ± 1.3 years post-treatment; 89.7% had had breast cancer. The intervention was feasible in that 36/39 (92.3%) of participants completed all questionnaires and daily diaries. It was also safe with no severe adverse events or rapid weight loss (average loss of 1.1 ± 2.3 pounds, p=0.008). Most adhered to TRE; 86.1% ate within a 10-h window at least 80% of the days, and the average eating window was 9.33 ± 1.05 h. Fatigue scores improved 5.3 ± 8.1 points on the FACIT-F fatigue subscale (p<0.001, effect size [ES]=0.55), 30.6 ± 35.9 points for the FACIT-F total score (p<0.001, ES=0.50), and -1.0 ± 1.7 points on the BFI (p<0.001, ES=-0.58). Conclusion:A 10-h TRE intervention was feasible and safe among survivors, and fatigue improved with a moderate effect size after two weeks. Limitations:This was a single-arm study, so it is possible that expectation effects were present for fatigue outcomes, independent of effects of TRE per se. However, this feasibility trial supports evaluation of TRE in randomized controlled trials to address persistent cancer-related fatigue.
Medical cancer treatment has evolved in a geometric manner since Gilman´s Mechlorethamine introduction into the bedside. Chemotherapy was born and rapidly proved its worth in different tumors and different clinical settings. Initially, the bright results were seen in hematologic malignancies, namely complete remissions in some types of leukemias and lymphomas and posteriorly in solid tumors, it changed the natural disease history in osteosarcoma, becoming adjuvant methotrexate the new overall survival drug in this malignancy. Many pediatric and young adults’ tumors comported complete remissions with chemotherapy, rendering them as curable diseases. As this, testicular cancer became the first example of a curable cancer model within advanced solid tumors (Cisplatin was the gladiator here). Even when the first clinical trial became from the sixties, during the seventies Oncologists became interested in the after-surgery chemo in breast cancer. Two pivotal trials (the US and Europe), continue showing that even nearly 40 years after, the overall survival benefit of adjuvant chemo in this disease is impressive. As many as with chemo, hormonotherapy proved and continues to prove its worth in postmenopausal breast cancer women. Adding to the before, two milestones in chemo history are the role of chemo in larynx organ preservation and its positive role in the colorectal cancer adjuvant setting. Taking as a profit chemo radio sensitizer power, the role of concomitant chemotherapy and radiotherapy came up to age: Head neck, rectal cancer, anal cancer only to mention some tumor topographies amenable to this combined approach with organ preservation objectives.
It is often difficult to accurately detect with the naked eye whether it is a benign or a malignant change. For this reason you should consult your doctor as soon as possible so the site can be examined. He or she must then decide whether you can wait and observe the area or whether a sample is already necessary for histological examination. In case of doubt it’s better to take a sample once too often than to be sorry. UVR exposure and therefore the extent of an individual’s skin sensitivity to UVR are the most determinants of carcinoma risk. Those with UVR-sensitive skin types are typically fair skinned and have a propensity to sunburn, blister, and/or freckle on exposure to UVR, indicators of enhanced susceptibility to UVR’s skin-damaging effects. For a given level of UVR exposure, skin cancer risk is highest in fair-skinned UVR-sensitive phenotypes, whereas darker skin colors have a more inherent photo protective capacity because of greater levels of melanin.
Statement of the Problem: Red blood cells (RBCs) are the most frequently transfused blood labile product. The “Donorvariation effect”, which refers to donor-todonor differences observed in both blood storage quality and 24h recovery, is probably a key factor in the efficiency of transfusion therapy. Donor variation effect may be associated with genetically determined features of RBCs and plasma. The aim of this study was to examine whether thedonor’s sex may independently affect the storage capacity of donated RBCs. Methodology & Theoretical Orientation: For this purpose, 14 leukoreduced units of RBC concentrates in CPD/SAGM (7 male–7 female) were stored for 42 days at 4-6oC. Several parameters of storage quality (including hemolysis, redox status etc) were examined before and throughout the storage period. SPSS was used for statistical analysis of the results.
Oncology feel includes forward-thinking preparing that is explicitly and extraordinarily intended to prepare estheticians in the adjustment of skincare therapies in spas to guarantee the wellbeing of individuals who are in the battle of battling malignancy. Oncology Esthetics includes high level training that is intended to give estheticians the. Information on the best way to change skincare/spa medicines to guarantee a protected result for your skin in the event that you are living. With malignancy. A great many people search for solace and help from the terrible results related with malignancy. Oncology facial therapies is a type of tasteful therapy that is intended to supplement clinical oncology therapy, tending to one of a kind skin worries that can emerge from oncology therapy while additionally offering significant integrative treatment to help lighten pressure and uneasiness related with combatting malignancy.
Introduction The dentition of head and neck cancer patients is of utmost importance once they receive actinotherapy, particularly as a result of patients reside longer once a course of head and neck radiation. Smart communication among the medicine team members (the radiation and medical oncologists, the external body part prosthodontist/dental medical specialist, ear-nose-and-throat doctor, rehabilitative doctor, nursing support) and therefore the patient is important at first and afterward as well as the overall medical man likewise. The aim of this primer for all those caring for patients with head and neck cancer is to underscore the vital role of the dental medical specialist throughout all phases of actinotherapy, and to supply tips to attenuate and stop dental complications like radiation-induced decay and ORN. Dentures ought to be avoided where doable. Removable prostheses square measure unseen in the dead of night. Oral lubricants/artificial secretion are also applied to the work surface of the dental appliance to enhance comfort and retention once water lessens is gift.
The epigenetic is a set of controlled reversible processes which causes inherited changes in the expression of genes Independent of the change in the nucleotide sequence of DNA. Changes in heterochromatin to yochromatin and vice versa. In DNA Methylation, Histone Modifications are considered as epigenetic mechanisms which regulates target genes in the transcription machine and On the other hand, the interaction of non-coding RNAs like Micro RNAs With target gene has identified their roles in the growth of differentiation and cell death. Therefore, epigenetic factors directly or indirectly change the expression of Micro RNAs in the cell. Certainly failure in these mechanisms leads to activating or inhibiting different messaging pathways and causing diseases such as cancer. As you know, the differentiation and survival of cells occur due to constant gene control patterns that also cancer is created as a result of a change in expression of the activity of carcinogenic genes or tumor suppressor genes. The expression of genes at the DNA and chromatin levels is regulated through epigenetic mechanisms. Of these, some small molecules and drugs that interact with specific sequences of DNA can be modified locally and allow the transcriptional machine to reach the target genes and, ultimately, to change the heterochromatin to the cochromatin, can be mentioned.
Wilms’ tumor (WT) is an embryonic tumor of kidney that belongs to paediatric age group. The etiopathology is highly complex due to interaction between genetic and epigenetic factors. The genetic heterogeneity of methylene tetrahydrofolate reductase (MTHFR) gene polymorphism increase “risk factor” of the disease. The present study has been designed to identify new gene variants single nucleotide polymorphism (SNP) of MTHFR using Sanger’s sequencing and decode the nucleotide sequences into corresponding amino acids to understand the translational events. Further, allele refractive mutation system with polymerase chain reaction (ARMS- PCR) was also used to confirm mutations (frequency) in the cases of WT and compare with age matched controls. Present findings reveal that genetic heterozygosity was observed in 20% cases of WT by substitution of nucleotide cytosine in to thymidine (C→T) followed by change of amino acid alanine is replaced by valine due to missense mutation. DNA sequencing data varies in different cases of WT that includes - first case shows four new SNPs -1) nucleotide cytosine is substitute by thymidine (C→T) followed by change in amino acid alanine is replaced by valine, 2) thymidine change into adenine (T→A) results in isoleucine→asparagine, 3) cytosine is substitute by adenine (C→A) results in isoleucine →asparagine, and 4) thymidine is substitute by cytosine (T→C), where phenylalanine →serine. Similarly, Second and third case of WT again showing the missense mutation, where the nucleotide cytosine is substitute by thymidine (C→T) followed by alanine→valine and thymidine into adenine (T→A) followed by change in isoleucine→asparagine, respectively. Based on bioinformatics analysis, the 3D structure predicted that the mutation in MTHFR gene modulate the functional activity of ligand binding sites either with protein or methotrexate. Collective findings of PCR and DNA sequencing suggests that these new gene variants which has not been reported earlier might have interfere in folate - metabolism during DNA methylation and increase genetic susceptibility and “risk factor” in WT cases.
Recently, we showed that cancer cells devoid of mitochondrial DNA (mtDNA) refered to as ρ0 cells recover their tumour formation ability in syngeneic mice only after the acquisition of the host mtDNA.1 Thus, ρ0 cancer cells are unable to form tumour unless mitochondria with mtDNA are acquired from normal cells in the tumour microenvironment to reconstitute their respiratory function.2 Therefore, mtDNA and mitochondrial respiration is needed for tumorigenesis. We explored the functional consequences of horizontal transfer of mitochondria, and found that pyrimidine biosynthesis, which is dependent on respiration-linked dihydroorotate dehydrogenase (DHODH), is essential for overcoming cell-cycle arrest and hence for promotion of tumour formation3. DHODH is present and primed in mtDNA-devoid cells, and it is fully re-activated by complex III/IV respiration and coenzyme Q (CoQ) redox-cycling recovered as a consequence of mitochondrial transfer. Moreover, respiration recovery, which is necessary for tumour cell proliferation allowing for tumour formation and progression, is associated with efficient de novo pyrimidine synthesis. We propose that re-activation of DHODH, a rate-limiting enzyme in the de novo pyrimidine synthesis, is the key event for triggering tumour growth following horizontal transfer of mitochondria into mtDNA-compromised cancer cells and that it is intimately linked to mitochondrial respiration. We therefore propose that DHODH is the critical link between de novo pyrimidine synthesis and respiration. We conclude that the CIII/CIV-CoQ-DHODH axis is the major promoter of tumour formation, making DHODH a potential broad-spectrum target for cancer therapy.
After the successful completion of the Oncology conference we are pleased to welcome you to the “Global Summit on Oncology and Cancer Therapy.” The congress is scheduled to take place on November 23-24, 2020 in the beautiful city of New York, USA. This 2020 Oncology Conference will give you exemplary experience and great insights in the field of research. The global Oncology/Cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025. Cancer is a disease, which involves the abnormal growth of cells that result in the formation of a tumor. However benign tumors are not Cancers. The abnormal tumor cells have the tendency to spread to other local tissues and may also spread to different parts of body through blood and lymphatic system. Different types of Cancers such as lung Cancer, colorectal, breast Cancer and others are predominant among the populace. Treatment of Cancer depends upon the stages of the disease progression. Chemotherapy is majorly used in the earlier stages whereas other therapy options such as targeted therapy drugs, immunological therapy drugs are used in late stage. Cancer has a widespread prevalence worldwide, which has led to rise in demand for Cancer drugs. The key factors that are responsible for the growth of the Oncology/ Cancer drugs market are surge in Cancer research, rise in geriatric population worldwide, and increase in number of collaborations between pharmaceutical companies. In addition, rise in healthcare expenditure worldwide is expected to boost the market expansion. Moreover, high market growth potential in developing nations, rise in number of pipeline products, and upsurge in demand for personalized medicines are expected to create new opportunities for the market players during the forecast period. However, adverse effects associated with the use of Cancer drugs and high costs related with Cancer drug development are the major factors that impede the growth of the market. According to drug class type, the targeted therapy segment occupied the largest Oncology/Cancer drugs market share in 2017. This is due to the ability of targeted therapies to kill only malignant cells, higher efficacy and higher survival rates associated with their use. The immunotherapy segment is expected to show fastest growth during the forecast period, registering a CAGR of 10.4%. This is attributed to surge in incidence of Cancer worldwide and high unmet medical needs in some countries. Immunotherapy drugs are widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body which makes them less toxic as compared to other modes of Cancer therapies. Moreover, continuous efforts in R&D to design and develop new immunotherapeutic for the treatment of various Cancer types serves as a key factor for the growth of the Oncology/Cancer drugs market. According to indication, the prostate Cancer segment occupied the largest Oncology/Cancer drugs market share in 2017. This is due to presence of huge geriatric population. The lung Cancer segment is expected to show fastest growth during the forecast period. This is due to technological developments in the field of Cancer diagnostics and rise in the awareness related to the early diagnosis of Cancer. translation. This will be possible due to the fact that the computer will begin to understand and analyse the meaning of the text. Our Mission • To provide the best platform were various ideas can be shared and information can be discussed. • To conduct conferences annually in each and every field of life science in various parts of the world to target maximum audiences. • To conduct outstanding events with our hard work. • To create some value worldwide.
Sonography of the Gastro-Intestinal Tract can reveal intra-mural tumours, Intra-mural hematoma, Lesions of Ampulla of Voter like benign and infiltrating mass lesions. Neoplastic lesion is usually a segment involvement, and shows irregularly thickened, hypo echoic and peristaltic wall with loss of normal layering pattern. It is usually a solitary stricture and has eccentric irregular luminal narrowing. It shows loss of normal Gut Signature. Enlargement of the involved segment seen Shouldering effect at the ends of stricture is most common feature. Enlarged lymphnodes around may be seen. Primary arising from wall itself and secondary are invasion from peri-Ampullary malignancy or distant metastasis. All these cases are compared and proved with gold standards like surgery and endoscopy. Some extra efforts taken during all routine or emergent ultrasonography examinations can be an effective non-invasive method to diagnose primarily hitherto unsuspected benign and malignant Gastro-Intestinal Tract lesions, so should be the investigation of choice.
Background: Injection of Tc99m to localize nodes for sentinel lymph node biopsy is reported by patients as very painful. The purpose of this study was to determine if anesthetic cream reduces pain associated with periareolar injection of Tc99m and to help elucidate conflicting literature regarding the efficacy of anesthetic cream for this procedure. Methods: A randomized, double-blind, placebo-controlled methodology was used for adult females with breast cancer undergoing periareolar injection of Tc99m for sentinel lymph node biopsy. Pain levels were compared using anesthetic cream (2.5% lidocaine/2.5% prilocaine) vs. placebo. Patient exclusion criteria included use of opioids or adjuvant pain medication or injecting Tc99m the day before surgery. The Numerical Rating Scale was used to assess pain levels immediately after the injections. Results: Comparing 23 experimental and 26 control pa tients, there was no significant difference between the experimental (median = 4) and the control group (median = 5) on level of pain experienced U=0.492, P > .05. Conclusions: The experimental group had a slightly lower median pain score; however, there was no statistically significant difference between those who used the cream compared with those who used a placebo, supporting the conclusion that anesthetic cream does not reduce pain during Tc99m injections. This study adds to the current literature to provide a stronger position that there is no benefit to using anesthetic cream for this procedure.
Background: The principal aim of health service providers in the field of breast cancer is to detect and treat lesions at an appropriate time. Therefore, identification of barriers to screening can be very helpful. The present study aimed to systematically review the qualitative studies for extracting and reporting the barriers of screening for breast cancer from the women’s perspective. Materials and Methods: In this systematic review; Pubmed, Google Scholar, Ovid Scopus, Cochrane Library, Iranmedex, and SID were searched using the keywords: screening barriers, cancer, qualitative studies, breast and their Persian equivalents, and the needed data were extracted and analyzed using an extraction table. To assess the quality of the studies, the Critical Appraisal Skills Program me (CASP) tool was used. Results: From 2,134 related articles that were found, 21 articles were eventually included in the study. The most important barriers from the point of view of 1,084 women were lack of knowledge, access barriers (financial, geographical, cultural), fear (of results and pain), performance of service providers, women's beliefs, procrastination of screening, embarrassment, long wait for getting an appointment, language problems, and previous negative experiences. Articles' assessment score was 68.9. Conclusions: Increasing women's knowledge, reducing the costs of screening services, cultural promotion for screening, presenting less painful methods, changing beliefs of health service providers, provision of privacy for giving service, decreasing the waiting time, and providing high quality services in a respectful manner can be effective ways to increase breast cancer screening.
Despite the effectiveness of mammography for early breast cancer detection, its’ utilization among Malaysian women remains low. This is possibly due to mammography screening being still opportunistic in nature. Conceptualizing screening behavior intentions utilizing Health Belief Model (HBM) is appropriate in understanding behavioral changes. As such, the study utilized HBM constructs in predicting the variance in adaptive behavior of mammography while controlling for moderating effects of knowledge and socio-demographic factors and mediating effects of self-efficacy using structural modeling fit analysis. Materials and methods A multi-stage, stratified random sampling method was utilized to select the polyclinics in Kuantan, Pahang. Five hundred and twenty Malaysian women aged between 35 and 70 years were selected randomly using sample size calculation at 5% type 1 error, p < 0.05, absolute error at 2%. Sets of the copyrighted, validated questionnaire were used to obtain the data. Structural equation modeling using Mplus was used to test the model. Indirect effects were included iteratively to the path model for evaluating moderating and mediating effects significance.
February 13, 2019 marked the 5th anniversary of The Male Breast Cancer Coalition (MBCC). This non-profit and awareness foundation was established with the objectives of saving lives through advocacy, education and a complete resource access of any and all support facilities and clinical information leading to the diagnosis, treatment and prevention of Male Breast Cancer. Origins of the MBCC came from the partnership between MBCC President and Co-founder, Cheri Ambrose of New Jersey and co-founder Bret Miller of Kansas City who is recorded as the youngest male worldwide to contract breast cancer. Bret was just 17 years old when he found a lump during a high school sports physical. For six years he was told by various doctors that it was nothing to worry about, just calcium that would dissipate as he got older. Bret underwent a mastectomy for breast cancer at the age of 24. He promised his doctor that if cured, he would become the face of breast cancer for me. He started his own awareness foundation, the Bret Miller 1T Foundation with his mother Peggy Miller as his manager and was attending many of the local 5k races and breast cancer events in Kansas City in an effort to bring awareness to the risk men face. Cheri had been working at her own organization in New Jersey known as the Blue Wave. The Blue Wave was born out of a need for awareness after a very dear friend had been diagnosed with breast cancer. He went from being a vibrant, outgoing person into a virtual hermit, shutting himself off from everyone due to embarrassment of having a women’s disease. Once connecting, through social media and an hour-long phone call with Peggy Miller, Bret’s mother and foundation manager, the two knew there was so much more they could do together and joined forces and never looked back. To date touching the lives of over 500 men diagnosed with breast cancer around the world.
Introduction: The treatment options for patients with radioactive-iodine refractory differentiated thyroid cancer include observation, multi-tyrosine kinase inhibitors (MTKIs), and traditional chemotherapy. An appropriate initial treatment with MTKI is challenging in clinical practice that the benefits outweigh the risk of any adverse events. Treatment strategies for Radioactive-Iodine Refractory Differentiated Thyroid Cancer: The activation of multiple downstream VEGFR signaling pathway, oncogenic mutated kinases (e.g. BRAF mutations), rearrangements of RET ,ALK, NTRK, and TERT promoter mutation are molecular mechanisms involved in RAI-R DTC. MTKIs demonstrated the clinical benefits either progression-free survival (11 to 18 months) or response rate (24-63%). Sorafenib and lenvatinib were approved by FDA for treatment of RAI-R DTC. However, up to 60% of patients with MTKIs required a dose reduction due to adverse events (AEs). The most frequent AEs are hypertension, diarrhea, weight loss, musocitis, fatigue,hand-foot syndrome, alopecia, and diarrhea. Therefore, close monitoring for disease progression and TSH-suppressive therapy are appropriate treatment for those patients with asymptomatic metastatic disease, or slow growing tumor. Initiation of treatment with MTKIs should be considered in symptomatic disease or rapid growing tumor. Conclusions: MTKIs demonstrate a promising approach. Sorafenib and lenvatinib have been approved by the FDA for the treatment of RAI-R DTC. However, multidisciplinary evaluation for adjustment made in order to take account of clinical benefit and risks should be performed before initiating MTKIs regarding to potential toxicities.
